Global Leukemia Therapeutics Market 2016-2020

Description: About Leukemia

Cancer that starts from hematopoietic stem cells of the bone marrow is referred to as leukemia. Leukemia can be chronic or acute depending on the maturity of the cells. Also, based on the bone marrow cells from which cancer starts, leukemia can be categorized as lymphocytic or myeloid.

The analysts forecast the leukemia therapeutics market to grow at a CAGR of 8.44% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the leukemia therapeutics market for 2016-2020. To calculate the market size, the report considers the the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of different types of leukemias.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Leukemia Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- F. Hoffmann-La Roche
- Novartis
- Bristol-Myers Squibb
- AbbVie
- Teva Pharmaceuticals

Other prominent vendors
- Altor BioScience
- Amgen
- ARIAD Pharmaceuticals
- Arno Therapeutics
- Astex Pharmaceuticals
- AstraZeneca
- Baxter Healthcare
- Bayer HealthCare
- Bellicum Pharmaceuticals
- Biogen
- Boehringer Ingelheim
- BioLineRx
- Boston Biomedical
- Celator Pharmaceuticals
- Celgene
- CTI BioPharma
- Chroma Therapeutics
- Chugai Pharmaceutical
- Cyclacel Pharmaceuticals
- Daiichi Sankyo
- Eisai
- Emergent BioSolutions
- Erytech Pharma
- Fate Therapeutics
- Genzyme
- Gilead Sciences
- GlaxoSmithKline
- iDD biotech
- Immune Pharmaceuticals
- Immunomedics
- Infinity Pharmaceuticals
- Innate Pharma
- Jazz Pharmaceuticals
- Juno Therapeutics
- Karyopharm Therapeutics
- Ligand Pharmaceuticals
- MEDA Pharmaceuticals
- MedImmune
- Merck
- Midas Pharma
- Molecular Templates
- MorphoSys
- Nippon Shinyaku
- Novo Nordisk
- Onconova Therapeutics
- Ono Pharmaceuticals
- Orphan Europe
- Otsuka
- Pfizer
- Portola Pharmaceuticals
- Regeneron Pharmaceuticals
- Sanofi
- Sigma-Tau Pharmaceuticals
- Stemline Therapeutics
- Sunesis Pharmaceuticals
- TG Therapeutics
- TheraMAB
- Tolero Pharmaceuticals
- XEME Biopharma
- Xencor
- ZIOPHARM Oncology

Market drivers
- Technological advances in the monitoring of leukemia
- For a full, detailed list, view the full report

Market challenges
- Limitations associated with current therapeutic options
- For a full, detailed list, view the full report

Market trends
- Rise in the development of combination therapies
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.
- Highlights

PART 02: Scope of the report
- Market overview
- Top-vendor offerings

PART 03: Market research methodology
- Research methodology
- Economic indicators

PART 04: Introduction
- Key market highlights

PART 05: Pipeline portfolio

PART 06: Market landscape
- Market overview
- Market size and forecast
- Five forces analysis

PART 07: Market segmentation by disease type

PART 08: Global CLL therapeutics market
- Market overview
- Total addressable market for global CLL therapeutics
- Vendors in the market

PART 09: Global ALL therapeutics market
- Market overview
- Vendors in the market

PART 10: Global AML therapeutics market
- Market overview
- Vendors in the market

PART 11: Global CML therapeutics market
- Market overview
- Vendors in the market

PART 12: Geographical segmentation
- Global leukemia therapeutics market by geography 2015-2020
- Leukemia therapeutics market in Americas
- Leukemia therapeutics market in EMEA
- Leukemia therapeutics market in APAC

PART 13: Market drivers
- Special regulatory designations for drugs
- Technological advances in the monitoring of leukemia
- Application for expanded indication approvals

PART 14: Impact of drivers

PART 15: Market challenges
- Complicated disease prognosis
- Financial and infrastructural constraints
- Limitations associated with current therapeutic options
- Delay in diagnosis

PART 16: Impact of drivers and challenges

PART 17: Market trends
- Rise in the development of combination therapies
- Patient assistance programs
- Focus on the identification of targets for the development of new therapies

PART 18: Vendor landscape
- Competitive scenario
- Other prominent vendors

PART 19: Key vendor analysis
- F. Hoffmann-La Roche
- Novartis
- Bristol-Myers Squibb
- AbbVie
- Teva Pharmaceuticals

PART 20: Appendix
- List of abbreviations

PART 21: About the Author

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Timeline of development of leukemia drugs
Exhibit 03: Impact of key customer segments on market 2015
Exhibit 04: Key buying criteria for global leukemia therapeutics market 2015
Exhibit 05: Pipeline portfolio: Global CLL therapeutics market
Exhibit 06: Pipeline portfolio: Global CML therapeutics market
Exhibit 07: Pipeline portfolio: Global ALL therapeutics market
Exhibit 08: Pipeline portfolio: Global AML therapeutics market
Exhibit 09: Global leukemia therapeutics market snapshot: Developed and emerging markets 2015
Exhibit 10: Distribution of people aged 60 years and over (millions)
Exhibit 11: Global leukemia therapeutics market 2015-2020 ($ billions)
Exhibit 12: Global leukemia therapeutics market segmentation: Growth cycle analysis
Exhibit 13: Five forces analysis
Exhibit 14: Segmentation of global leukemia therapeutics market by type of disease 2015
Exhibit 15: Global leukemia therapeutics market by type of disease 2015-2020
Exhibit 16: Global leukemia therapeutics market segmentation: Growth lifecycle analysis
Exhibit 17: Global CLL therapeutics market 2015-2020 ($ billions)
Exhibit 18: Total addressable market for global CLL therapeutics market 2015-2020 ($ billions)
Exhibit 19: Major vendors in the CLL therapeutics market 2015
Exhibit 20: Global ALL therapeutics market 2015-2020 ($ billions)
Exhibit 21: Major vendors in ALL therapeutics market 2015
Exhibit 22: Global AML therapeutics market 2015-2020 ($ millions)
Exhibit 23: Major vendors in global AML therapeutics market
Exhibit 24: Global CML therapeutics market 2015-2020 ($ billions)
Exhibit 25: Major vendors in global CML therapeutics market
Exhibit 26: Global leukemia therapeutics market by geography 2015-2020
Exhibit 27: Percentage share of global leukemia therapeutics market by geography 2015 and 2020
Exhibit 28: Global share of leukemia therapeutics market by geography 2015
Exhibit 29: Revenue of global leukemia therapeutics market by geography 2015-2020 ($ billions)
Exhibit 30: Revenue/growth outlook in different countries/regions 2015
Exhibit 31: Global leukemia therapeutics market segmentation by region: Market growth lifecycle analysis 2015
Exhibit 32: Leukemia therapeutics market in different regions by type of disease
Exhibit 33: Opportunity analysis of leukemia therapeutics market in Americas
Exhibit 34: Percentage share of new cases of leukemia in US 2014
Exhibit 35: Hispanic population percentage in US total population
Exhibit 36: Leukemia therapeutics market in Americas 2015-2020 ($ billions)
Exhibit 37: Opportunity analysis of leukemia therapeutics market in EMEA
Exhibit 38: Leukemia therapeutics market in EMEA 2015-2020 ($ billions)
Exhibit 39: Opportunity analysis of leukemia therapeutics market in APAC
Exhibit 40: Leukemia therapeutics market in APAC 2015-2020 ($ billions)
Exhibit 41: Orphan designation pipeline drugs for leukemia
Exhibit 42: Breakthrough therapy designation drugs for leukemia
Exhibit 43: Expanded indication approval drugs in the treatment of leukemia
Exhibit 44: Impact of drivers
Exhibit 45: Cost of therapy for some leukemia drugs
Exhibit 46: Impact of drivers and challenges
Exhibit 47: Combination therapies under development for the treatment of leukemia
Exhibit 48: Leukemia drugs with patient assistance programs
Exhibit 49: Key vendors ranking 2015
Exhibit 50: Geographical presence of key vendors in leukemia therapeutics market 2015
Exhibit 51: Competitive landscape of vendors in global leukemia therapeutics market 2015-2020
Exhibit 52: F. Hoffmann-La Roche: Profile
Exhibit 53: F. Hoffmann-La Roche: Strength analysis
Exhibit 54: F. Hoffmann-La Roche: Growth strategy matrix
Exhibit 55: F. Hoffmann-La Roche: Opportunity assessment
Exhibit 56: F. Hoffmann-La Roche: YoY revenue and growth rate of Rituxan/MabThera 2013-2015 ($ billions)
Exhibit 57: F. Hoffmann-La Roche: Rituxan/MabThera geographic segmentation by revenue 2015
Exhibit 58: Novartis: Profile
Exhibit 59: Novartis: Strength analysis
Exhibit 60: Novartis: Growth strategy matrix
Exhibit 61: Novartis: Opportunity assessment
Exhibit 62: Bristol-Myers Squibb: Profile
Exhibit 63: Bristol-Myers Squibb: Strength analysis
Exhibit 64: Bristol-Myers Squibb: Growth strategy matrix
Exhibit 65: Bristol-Myers Squibb: Opportunity assessment
Exhibit 66: AbbVie: Profile
Exhibit 67: AbbVie: Strength analysis
Exhibit 68: AbbVie: Growth strategy matrix
Exhibit 69: AbbVie: Opportunity assessment
Exhibit 70: Teva Pharmaceuticals: Profile
Exhibit 71: Teva Pharmaceuticals: Strength analysis
Exhibit 72: Teva Pharmaceuticals: Growth strategy matrix
Exhibit 73: Teva Pharmaceuticals: Opportunity assessment
Exhibit 74: Teva Pharmaceuticals: YoY revenue and growth rate of TREANDA 2013-2015 ($ millions)

Exhibit 43: Expanded indication approval drugs in the treatment of leukemia

Exhibit 44: Impact of drivers
Exhibit 45: Cost of therapy for some leukemia drugs
Exhibit 46: Impact of drivers and challenges
Exhibit 47: Combination therapies under development for the treatment of leukemia
Exhibit 48: Leukemia drugs with patient assistance programs
Exhibit 49: Key vendors ranking 2015
Exhibit 50: Geographical presence of key vendors in leukemia therapeutics market 2015
Exhibit 51: Competitive landscape of vendors in global leukemia therapeutics market 2015-2020
Exhibit 52: F. Hoffmann-La Roche: Profile
Exhibit 53: F. Hoffmann-La Roche: Strength analysis
Exhibit 54: F. Hoffmann-La Roche: Growth strategy matrix
Exhibit 55: F. Hoffmann-La Roche: Opportunity assessment
Exhibit 56: F. Hoffmann-La Roche: YoY revenue and growth rate of Rituxan/MabThera 2013-2015 ($ billions)
Exhibit 57: F. Hoffmann-La Roche: Rituxan/MabThera geographic segmentation by revenue 2015
Exhibit 58: Novartis: Profile
Exhibit 59: Novartis: Strength analysis
Exhibit 60: Novartis: Growth strategy matrix
Exhibit 61: Novartis: Opportunity assessment
Exhibit 62: Bristol-Myers Squibb: Profile
Exhibit 63: Bristol-Myers Squibb: Strength analysis
Exhibit 64: Bristol-Myers Squibb: Growth strategy matrix
Exhibit 65: Bristol-Myers Squibb: Opportunity assessment
Exhibit 66: AbbVie: Profile
Exhibit 67: AbbVie: Strength analysis
Exhibit 68: AbbVie: Growth strategy matrix
Exhibit 69: AbbVie: Opportunity assessment
Exhibit 70: Teva Pharmaceuticals: Profile
Exhibit 71: Teva Pharmaceuticals: Strength analysis
Exhibit 72: Teva Pharmaceuticals: Growth strategy matrix
Exhibit 73: Teva Pharmaceuticals: Opportunity assessment
Exhibit 74: Teva Pharmaceuticals: YoY revenue and growth rate of TREANDA 2013-2015 ($ millions)

Ordering:  
Order Online - http://www.researchandmarkets.com/reports/3883908/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Global Leukemia Therapeutics Market 2016-2020
Web Address: http://www.researchandmarkets.com/reports/3883908/
Office Code: SC2GZILF

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 2500</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 5 Users</td>
<td></td>
<td>USD 3000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 10000</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof [ ]

First Name: ___________________________ Last Name: ___________________________

Email Address:* ___________________________

Job Title: ___________________________

Organisation: ___________________________

Address: ___________________________

City: ___________________________

Postal / Zip Code: ___________________________

Country: ___________________________

Phone Number: ___________________________

Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
- Account number: 833 130 83
- Sort code: 98-53-30
- Swift code: ULSBIE2D
- IBAN number: IE78ULSB98533083313083
- Bank Address: Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World